Centocor regulatory update

The FDA granted marketing approval for CNTO's Remicade infliximab blocker of tumor necrosis factor alpha (TNF-a) to treat patients with moderately to severely active Crohn's disease who do not respond to conventional therapy and for those with fistulizing Crohn's disease. CNTO expects to launch the product, which it will sell to distributors for $450 per vial, by early October. CNTO said the average Crohn's patient requires 3-4 vials of Remicade per infusion (see online links, BioCentury, Part I). ...